Sun, Dec 21, 2014, 9:29 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Ampio Pharmaceuticals, Inc. Message Board

  • dkotanto dkotanto Aug 15, 2013 9:37 PM Flag

    About the data

    The company has clearly addressed "the data" piece in their PRESS RELEASE. I emphasize PRESS RELEASE as it was not meant to be an in depth scientific disclosure of data.

    Here's their CEO's comment, but wait a minute! He is saying that it looks like Ampion keeps on working past the 12 week treatment!!! Wouldn't that be an important reason to wait and present it in their data? Wouldn't that be more impressive which further differentiates their drug from the rest? But of course it would, but the shorts in this board naturally fail to mention these little details...

    CEO's comment::

    Mr. Macaluso further noted “Investigators will continue to monitor the Ampion-treated patients because the data suggest improvement in pain and function beyond the 12 week primary endpoint. Detailed 12 week data analysis from the SPRING study will be released following discussions with the FDA and will be presented at upcoming medical conferences.”

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
AMPE
3.46-0.18(-4.95%)Dec 19 4:09 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.